University of Cambridge Veterinary School
In an experiment involving the use of N-acetylcarnosine in dogs suffering form cataracts, researchers found that its effects are more pronounced in the early form of the disease. Scientists from the Department of Veterinary Medicine, University of Cambridge (UK), wanted to see if a topical antioxidant containing N-acetylcarnosine had any effect on dogs suffering from different stages of cataract. They examined 30 dogs of different breeds and used eye drops containing 2% N-acetylcarnosine. The drops were used three times a day, and the dogs were examined at regular intervals, by using direct and indirect ophthalmoscopy and slitlamp biomicroscopy (a method whereby the examiner looks directly and in detail into the eye). Specialist photographs were then taken. The results showed that improvement of cataract was found in all eyes examined, but this improvement was particularly relevant in cases where the cataract was in the early stages(immature cataract).
Reference: Williams DL, Munday P. Vet Ophthalmol. 2006;9(5):311-6.The effect of a topical antioxidant formulation including N-acetyl carnosine on canine cataract: a preliminary study). Rejuvenation Res. 2004 Fall;7(3):186-98.
Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops.
Babizhayev MA.Innovative Vision Products, Inc. Moscow Division, Ivanovskaya 20, Suite
74, Moscow 127434, Russian Federation. x
The purpose of this study was to examine using the original halometer glare test of the type of visual impairment mediated by the increased glare sensitivity (halos) and associated with poorer visual function in both the better and worse eyes of older adult drivers and older drivers with cataract. The clinically validated (by Innovative Vision Products Inc.) formula of 1% N-acetylcarnosine (NAC) lubricant eye drops were applied
topically to the eyes of older drivers to reduce glare disability and improve distance acuities for driving. This was a randomized, double-blind, placebo-controlled study. The examined subjects consisted of 65 older adults, with cataract in one or both eyes, and 72 adult drivers who did not have cataract in either eye. In the control group, comparison with baseline values showed some variability of data in gradual worsening of glare sensitivity at red and green targets and minimal VA changes over 4 months. In the NACtreated group, 4-month follow-up generally showed an improvement in VA and a
significant improvement in glare sensitivity at red and green targets was documented in worse and better eyes using a critical cut point halometer score for driving. The NACtreated eyes had statistically significant difference in VA, glare sensitivity compared with the control group ( p < 0.001) at 4-month timepoint of treatment, as supported by the overall t-test results of the ratio of the follow-up data to the baseline values. Tolerability of NAC eyedrops was good in almost all patients, with no reports of ocular or systemic adverse effects. It would be advisable for traffic safety if a Halometer glare sensitivity test
was implemented for vehicles and/or was regularly added to the requirements for a driver’s licence. The results of this study provide a substantial basis for further evaluation of NAC in the treatment and prevention of vision impairment in the older population of drivers for legal driving. The developed ophthalmic drug NAC formula showed potential for the non-surgical treatment of age-related cataracts